Source:http://linkedlifedata.com/resource/pubmed/id/12665679
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-3-31
|
| pubmed:abstractText |
Thirty-two patients with nasal NK/T-cell lymphoma and disseminated disease (lung, skin, and bone marrow) were treated with an intensive combined therapy that consisted of three cycles of CMED (cyclophosphamide 2 g/m(2), metothrexate 200 mg/m(2), etoposide 600 mg/m(2), and dexamethasone 80 mg/m(2) with leucovorin rescue administered 24 h after) every 14 d, following high-dose radiotherapy: 55 Gy in 20 sesions to centrofacial region and three cycles more of the same chemotherapy regimen. To ameliorate the presence of severe granulocytopenia, granulocyte colony-stimulating factor, 5 microg/kg, daily for 14 d, begun on d 2 after chemotherapy, was administered. Complete response was achieved in 21 cases (65%); failure or progression was observed in 11 cases (35%). With a median follow-up of 69.1 mo, relapse has not been observed; thus, actuarial curves at 5 yr showed that event-free survival (EFS) is 100% in 21 patients and overall survival (OS) is 65%. Granulocytopenia grade IV was observed in 15% cycles, Nonhematological toxicity was mild and well tolerated. Radiotherapy was well tolerated; only mild mucositis was observed. Nasal NK/T-cell lymphoma is an rare presentation of malignant lymphoma (<1% of all cases) with a worse prognosis; less than 5% patients are alive free of disease at 1 yr. The use of intensive more specific chemotherapy and high dose of local radiotherapy, appear to be an excellent therapeutic approach with improvement in EFS and OS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1357-0560
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
13-7
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:12665679-Adult,
pubmed-meshheading:12665679-Aged,
pubmed-meshheading:12665679-Agranulocytosis,
pubmed-meshheading:12665679-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12665679-Bone Marrow Neoplasms,
pubmed-meshheading:12665679-Cyclophosphamide,
pubmed-meshheading:12665679-Dexamethasone,
pubmed-meshheading:12665679-Disease-Free Survival,
pubmed-meshheading:12665679-Etoposide,
pubmed-meshheading:12665679-Female,
pubmed-meshheading:12665679-Follow-Up Studies,
pubmed-meshheading:12665679-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:12665679-Humans,
pubmed-meshheading:12665679-Killer Cells, Natural,
pubmed-meshheading:12665679-Leucovorin,
pubmed-meshheading:12665679-Lung Neoplasms,
pubmed-meshheading:12665679-Lymphoma, T-Cell,
pubmed-meshheading:12665679-Male,
pubmed-meshheading:12665679-Methotrexate,
pubmed-meshheading:12665679-Middle Aged,
pubmed-meshheading:12665679-Nose Neoplasms,
pubmed-meshheading:12665679-Radiotherapy, Adjuvant,
pubmed-meshheading:12665679-Remission Induction,
pubmed-meshheading:12665679-Skin Neoplasms,
pubmed-meshheading:12665679-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy.
|
| pubmed:affiliation |
Oncological Research Unit, Oncology Hospital, National Medical Center, IMSS, México. agaviles@avantel.net
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|